SLC35A2 and colorectal carcinoma: The analysis revealed that CRC patients with high expression of SLC35A2 had a lower relapse-free survival compared to those with low expression, indicating a poorer outcome for patients with high SLC35A2 expression (hazard ratio (HR) = 1.33, p for trend = 0.0066).